VertisPro is a Singapore-based clinical trial intelligence company. We help pharma and biotech sponsors make better site selection, patient recruitment, and referral network decisions for Phase 2 and Phase 3 trials, particularly in rare disease, oncology, and immunology, where the eligible patient population is narrow and standard approaches consistently fall short. The problem with standard approaches Most site selection relies on historical enrollment databases and CRO site networks built for common, high-prevalence indications. For rare or complex programs, this approach fails in a predictable way: it points sponsors toward sites that look productive on paper but sit outside the actual patient flow for that specific indication. The patients exist, but the standard tools cannot find them. And once sites are open, traditional recruitment assumes patients will present through standard referral channels. For rare and complex indications, most will not. How VertisPro works We analyse patient behavioral signals to understand how patients with a specific condition actually move through the healthcare system: where they search for information, where they receive their diagnosis, and which community physicians are controlling referral flow upstream of any clinical trial site. This produces a site selection recommendation grounded in current patient geography, not historical enrollment averages. The same intelligence drives our digital recruitment programs, which reach patients geo-targeted to site catchment areas before they enter any referral chain. Our three core offerings are: Site Selection and Feasibility: A scored, ranked site list built from behavioral and referral signal data, identifying where the right patients are concentrated right now. Designed for sponsors who are about to open sites in a new geography or whose current site mix is underperforming. Digital Patient Recruitment: An always-on digital program that identifies and engages patients geo-targeted to site catchment areas, pre-screens them, and coordinates referral to the nearest trial site. Designed for sponsors whose enrollment is running behind projections or who need to reach patients beyond the immediate site network. Referral Center Intelligence: A mapping of the upstream community physicians and referral centers controlling patient flow to any given trial site. Designed for sponsors running rare disease or specialty programs where the bottleneck is not site capacity but physician awareness and referral behaviour. Who we work with We work with global pharma and biotech sponsors running Phase 2 and Phase 3 programs, including companies opening international sites for the first time. Our work is most valuable where the indication is rare or first-in-class, the patient population is geographically dispersed, and a poor site selection or slow enrollment cannot be recovered from mid-trial.
I'm Harshad, CEO and Co-founder at VertisPro, a Singapore-based company building data intelligence tools for clinical trial site selection, patient recruitment, and referral network mapping. I have 20+ years in HealthTech and a track record of building and scaling HealthTech companies. The work at VertisPro draws directly on what I've seen go wrong in clinical operations at scale.
The problem we solve is specific: standard site selection relies on historical enrollment databases and CRO site networks built for high-prevalence indications. For rare disease, first-in-class drugs, and complex Phase 2/3 programs, that approach consistently points sponsors to the wrong sites. Sites that look productive on paper but sit outside the actual patient flow for that indication. And once sites are open, traditional recruitment assumes patients will find their way in. Most don't.
VertisPro's approach is different. We map patient behavioral signals: how patients with specific conditions actually move through the healthcare system, where they search, where they get diagnosed, and which community physicians are controlling referral flow upstream of any trial site. That intelligence drives three things: a site selection report grounded in where patients are right now; a digital recruitment program that reaches patients geo-targeted to site catchment areas before they enter any referral chain; and a referral center intelligence map that identifies which upstream physicians control patient flow to each site.
We work with global pharma and biotech sponsors on Phase 2 and Phase 3 trials, particularly in oncology, immunology, and rare disease, where the eligible population is narrow and the margin for a poor site selection decision is zero.
I'm in Switzerland to meet clinical-stage companies planning their first international trials or whose current enrollment is running behind projections. If you're about to open sites outside your home market, struggling to hit recruitment targets, or want a clearer picture of your referral network, I'm happy to talk through what we see in your indication.